Sisomicin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Sisomicin
DrugBank Accession Number
DB12604
Background

Sisomicin has been used in trials studying the treatment of Pyoderma.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 447.5264
Monoisotopic: 447.269298563
Chemical Formula
C19H37N5O7
Synonyms
  • Sisomicin
External IDs
  • SCH 13475

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Sisomicin which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Sisomicin which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Sisomicin which could result in a higher serum level.
AcenocoumarolThe risk or severity of bleeding can be increased when Sisomicin is combined with Acenocoumarol.
AcetaminophenAcetaminophen may decrease the excretion rate of Sisomicin which could result in a higher serum level.
AcetylcholineThe therapeutic efficacy of Acetylcholine can be decreased when used in combination with Sisomicin.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Sisomicin is combined with Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Sisomicin which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
J01GB08 — Sisomicin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminocyclitol glycosides
Alternative Parents
O-glycosyl compounds / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Monosaccharides / Tertiary alcohols / 1,2-aminoalcohols / Oxacyclic compounds / Dialkylamines
show 4 more
Substituents
1,2-aminoalcohol / Acetal / Alcohol / Aliphatic heteromonocyclic compound / Amine / Amino cyclitol glycoside / Aminocyclitol or derivatives / Cyclic alcohol / Cyclitol or derivatives / Cyclohexanol
show 17 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
monosaccharide derivative, aminoglycoside antibiotic, amino cyclitol glycoside, beta-L-arabinoside (CHEBI:9169)
Affected organisms
Not Available

Chemical Identifiers

UNII
X55XSL74YQ
CAS number
32385-11-8
InChI Key
URWAJWIAIPFPJE-YFMIWBNJSA-N
InChI
InChI=1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12+,13-,14-,15+,16-,17-,18-,19+/m1/s1
IUPAC Name
(2R,3R,4R,5R)-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol
SMILES
[H][C@@]1(N)CC=C(CN)O[C@]1([H])O[C@]1([H])[C@@]([H])(N)C[C@@]([H])(N)[C@]([H])(O[C@@]2([H])OC[C@](C)(O)[C@]([H])(NC)[C@@]2([H])O)[C@@]1([H])O

References

General References
Not Available
KEGG Compound
C00494
PubChem Compound
36119
PubChem Substance
347828820
ChemSpider
33222
RxNav
9806
ChEBI
9169
ChEMBL
CHEMBL221886
ZINC
ZINC000056870809
PDBe Ligand
SIS
Wikipedia
Sisomicin
PDB Entries
4f8u / 4f8v / 5c4l / 5u08 / 6bbz / 6bc3 / 6bc7 / 6cap / 6car / 6mb4
show 3 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4WithdrawnTreatmentPyoderma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility15.6 mg/mLALOGPS
logP-2ALOGPS
logP-4.3ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)12.55ChemAxon
pKa (Strongest Basic)9.88ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area213.72 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity110.32 m3·mol-1ChemAxon
Polarizability46.45 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0002-0000900000-c257d090490406f3043c
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0002-0010900000-e957e2ece6cb00541b9b
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0f79-2960000000-e4019234db0edb127967
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0zmi-9500000000-581186dcec1f1ab9320d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0ab9-9100000000-ccd5691ace392b03e90b
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0002-0000900000-060193de09eeb53e3e1a
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0230-0274900000-3f1be89196073a2aef6c
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0ir0-0970000000-e8083a0ffe7791382e2b
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-0920000000-eea6c730484f1d2fcc1d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0nmi-3900000000-df6cc4b9d9d4d7f88835
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0591000000-0785a7498e5373b2d8a0
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03fr-1910000000-e0b1b4029b0e6a0848b9
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03e9-6900000000-fbac675bcbadc5d332ff
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-9300000000-71a42721119dc4209a6f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-9100000000-f588e80a7fdccf35f2e1
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-00di-0109600000-acd2c9f9fca4c7cfba95

Drug created on October 20, 2016 23:10 / Updated on February 21, 2021 18:53